Discharge Guidelines for Prophylactic Anticoagulation for Trauma Patients

exp date isn't null, but text field is

Objectives

To provide standardized recommendations for prophylactic anticoagulation for trauma patients at the time of hospital discharge

All non-ambulatory patients or patients with spine trauma, orthopedic injuries, or traumatic brain injury will have a Caprini Score calculated at the time of discharge. The choice of anticoagulation will be determined based on Caprini score, injuries, procedures, and existing medical conditions. Refer to the table on the next page for recommendations. Many patients will require prophylaxis for a total of four weeks from the time of injury. Two weeks may be adequate if the patient is weight bearing and has a low risk injury/procedure or a moderate risk injury/procedure in addition to a low Caprini score (≤7).

If warfarin is selected, patients should receive low molecular weight heparin (LMWH) bridiging until a therapeutic INR (2-3) is achieved. The patient’s primary care phyisician (PCP) will be contacted to arrange warfarin follow up. If the patient does not have a PCP, a referral to the Michigan Medicine Anticoagulation Clinic will be made with the trauma/burn attending at time of discharge designated as the patient’s PCP (patients can only be seen at the Anticoagulation Clinic if their primary care physician is affiliated with Michigan Medicine). A referral to the Michigan Medicine Anticoagulation Clinic can also be made if the patient’s PCP is affiliated with Michigan Medicine.

 

Patient Characteristics

Caprini Score >7

Caprini Score ≤ 7

High risk for Bleeding (defined as coagulopathy, recent hemorrhagic stroke, or recent GI Bleed)

High Risk Injury/Procedure

  • THA (including revision or liner change)
  • TKA
  • Open treatment of femoral neck fracture
  • Femur fracture s/p surgical repair
  • Pelvic fracture s/p surgical repair
  • Peritrochanteric hip fracture s/p surgical repair
  • Pelvic osteotomy

Preferred

  • Rivaroxaban 10 mg oral once daily for 4 weeks

If CrCl is <30 mL/min or DOAC is not covered by insurance

  • Warfarin (goal INR 2-3) for 4 weeks¥
  • Choice of anticoagulation per attending discretion
  • Generally, no pharmacologic discharge prophylaxis is recommended
  • Initiate pharmacologic prophylaxis once bleeding risk has subsided
  • Compression stockings recommended

Moderate Risk Injury/Procedure

  • Tibia Diaphyseal Fracture IMN
  • Hip Scope
  • Ankle Pilon s/p surgical repair
  • Tibial Plateau s/p surgical repair
  • Shoulder Arthroplasty

Preferred

  • Rivaroxaban 10 mg daily for 4 weeks

If DOAC is not covered by insurance

  • Enoxaparin 30 mg twice daily

If CrCl is <30 mL/min

  • Aspirin 81 mg daily for 4 weeks

Preferred

  • Rivaroxaban 10 mg daily for 2 weeks OR aspirin 81 mg daily for 2 weeks*

If DOAC is not covered by insurance

  • Enoxaparin 30 mg twice daily

If CrCl is <30 mL/min

  • Aspirin 81 mg daily for 4 weeks
  • No pharmacologic prophylaxis recommended
  • Initiate pharmacologic prophylaxis once bleeding risk has subsided
  • Compression stockings recommended

Low Risk Injury/Procedure

  • All Upper Extremity fractures except should arthroplasty
  • Hardware removal
  • Knee Scopes
  • Ankle fracture s/p surgical repair
  • Foot fracture s/p surgical repair

Preferred

  • Rivaroxaban 10 mg daily OR aspirin 81 mg daily for 2 weeks

If CrCl is <30 mL/min

  • Aspirin 81 mg daily for 2 weeks*
  • No discharge prophylaxis
  • No discharge prophylaxis
  • Consider initiation of pharmacologic prophylaxis if bleeding risk has subsided and Caprini score is now >7
  • Calculate duration from time of injury
  • *Patients with a pending operative intervention within two weeks of discharge should be discharged on LMWH for a total of 4 weeks
  • Avoid enoxaparin in patients receiving renal replacement therapy
  • ¥Bridge with SQ enoxaparin 30 mg twice daily (preferred) or SQ heparin 5000 units three times daily (for CrCl <30 mL/min)
  • Consider discharge prophylaxis in patients with a Caprini score >7 and an active cancer diagnosis, prior VTE, or a known hypercoagulability disorder

Caprini Score

       Each Risk Factor Represents 1 Point
  Age 41-60 years
  Minor surgery planned
  History of prior major surgery (<1 month)
  Varicose veins
  History of inflammatory bowel disease
  Swollen legs (current)
  Obesity (BMI > 25)
  Acute myocardial infarction
  Congestive heart failure (< 1 month)
  Sepsis (<1 month)
  Serious lung disease incl. pneumonia (<1 month)
  Abnormal pulmonary function (COPD)
  Medical patient currently at bed rest
  Orther risk factors ____________________

 

        Each Risk Factor Represents 2 Points
  Age 60-74 years
  Arthroscopic surgery
  Malignancy (present or previous)
  Major surgery (>45 minutes)
  Laparoscopic surgery (>45 minutes)
  Patient confined to bed (>72 hours)
  Immobilizing plaster cast (<1 month)
  Central Venous Catheter

 

       Each Risk Factor Represents 5 Points
  Elective major lower extremity arthroplasty
  Hip, pelvis or leg fracture (<1 month)
  Stroke (<1 month)
  Multiple trauma (<1 month)
  Acute spinal cord injury (paralysis)  (< 1 month)

 

       Age over 75 years
  History of DVT/PE
  Family history of thrombosis *
  Positive Factor V Leiden
  Positive Prothrombin 20210A 
  Elevated serum homocysteine
  Positive lupus anticoagulant
  Elevated anticardiolipin antibodies
  Heparin-induced thrombocytopenia (HIT)
  Other congenital or acquired thrombophilia  If Yes:
_______________________________
  * most frequently missed risk factor

 

       For Women Only (Each Represents 1 Point)
  Oral contraceptives or hormone replacement therapy
  Pregnancy or postpartum (<1 month)
  History of unexplained stillborn infant,
recurrent spontaneous abortion (≥3),
premature birth with toxemia or growth-
restricting infant

Total Risk Factor Score ___________

Special Thanks

Attribution

If reusing this content please use the following information to provide credit to the content authors:  

  1. Title: Discharge Guidelines for Prophylactic Anticoagulation for Trauma Patients
  2. Author:  Michigan Medicine
  3. Source: https://ecosystem.tactuum.com/
  4. License: “CC BY-NC 4.0”

Discharge Guidelines for Prophylactic Anticoagulation for Trauma Patients,  Michigan Medicine, Dept of Surgery,  “CC BY-NC 4.0”

References
  • Sagi HC, Ahn J, Ciesla D, et al. Venous Thromboembolism Prophylaxis in Orthopedic Trauma Patients: A Survey of OTA Member Practice Patterns and OTA Expert Panel Recommendations. J Orthop Trauma. 2015 Oct; 29 (10): e355-62. doi: 10.1097/BOT.0000000000000387
  • Prevention of VTE in orthopedic surgery patients. American College of Chest Physicians. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141 (suppl 2):e278S-e325S.
  • Early venous thromboembolism prophylaxis with enoxaparin in patients with blunt traumatic brain injury. J Trauma. 2008 Nov;65(5):1021-6; discussion 1026-7
  • Brain Trauma Foundation; American Association of Neurological Surgeons; Congress of Neurological Surgeons; Joint Section on Neurotrauma and Critical Care, AANS/CNS: Guidelines for the management of severe traumatic brain injury. V. Deep vein thrombosis prophylaxis.J Neurotrauma. 2007;24 Suppl 1:S32-6. No abstract available. Erratum in: J Neurotrauma. 2008 Mar;25(3):276-8.
  • American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? Chest 2009; 135:513-520.
  • Xarelto package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2011 July. http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf#zoom=100 (accessed 2011 December 1).
  • Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;356:2765-75.
  • Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-bline, randomized controlled trial. Lancet 2008;372:31-9.
  • Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86.
  • Turpie AGG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomized trial. Lancet 2009;373:1673-80.
  • Turpie AGG, Kreutz R, Llau J, Norrving B, Haas S. Management consensus guidance for the use of rivaroxaban – an oral direct factor Xa inhibitor. Thromb Haemost. 2012;108:876-886.
  • Machado-Aranda DA, Jakubus JL, Wahl WL, Cherry-Bukoweic JR, To KB, Park PK, Raghavendran K, Napolitano LM, Hemmila MR. Reduction in venous thromboembolism events: trauma performance quality improvement and loop closure through participation in state-wide quality collaborative. J Am Coll Surg. 2015 Sep;221(3):661-8.
  • Jacobs BN, Cain-Nielsen AH, Jakubus JL, Mikhail JN, Faith JJ, Regenbogen SE, Hemmila MR. Unfractionated heparin versus low molecular-weight heparin for venous thromboembolism prophylaxis in trauma. J Trauma Acute Care Surg. 2017 Jul;83(1):151-158.
  • Samama CM, Laporte S, Rosencher N, et al. Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery. NEJM. 2020; 382:1916-1925

Last reviewed: 09 June 2021